NL194940C - Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. - Google Patents
Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. Download PDFInfo
- Publication number
- NL194940C NL194940C NL9401414A NL9401414A NL194940C NL 194940 C NL194940 C NL 194940C NL 9401414 A NL9401414 A NL 9401414A NL 9401414 A NL9401414 A NL 9401414A NL 194940 C NL194940 C NL 194940C
- Authority
- NL
- Netherlands
- Prior art keywords
- virus
- vaccine
- prrs
- sows
- pig
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 134
- 229960005486 vaccine Drugs 0.000 title claims description 92
- 208000011580 syndromic disease Diseases 0.000 title claims description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 title description 5
- 241000282898 Sus scrofa Species 0.000 claims description 56
- 208000015181 infectious disease Diseases 0.000 claims description 51
- 210000004072 lung Anatomy 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 32
- 239000002671 adjuvant Substances 0.000 claims description 29
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 22
- 108700026244 Open Reading Frames Proteins 0.000 claims description 19
- 210000001132 alveolar macrophage Anatomy 0.000 claims description 19
- 230000003612 virological effect Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 210000002540 macrophage Anatomy 0.000 claims description 13
- 230000000241 respiratory effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 206010069767 H1N1 influenza Diseases 0.000 claims description 8
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims description 8
- 230000036755 cellular response Effects 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 8
- 201000010740 swine influenza Diseases 0.000 claims description 8
- 208000005577 Gastroenteritis Diseases 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 238000003501 co-culture Methods 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 229940031348 multivalent vaccine Drugs 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000606807 Glaesserella parasuis Species 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 241000589902 Leptospira Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 231100000676 disease causative agent Toxicity 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims description 2
- 108020004084 membrane receptors Proteins 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 210000004754 hybrid cell Anatomy 0.000 claims 2
- 241000588779 Bordetella bronchiseptica Species 0.000 claims 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims 1
- 241000480044 IAS virus Species 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 241000606856 Pasteurella multocida Species 0.000 claims 1
- 241000711493 Porcine respiratory coronavirus Species 0.000 claims 1
- 229940031416 bivalent vaccine Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940051027 pasteurella multocida Drugs 0.000 claims 1
- 241000061450 x Ascocenda Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 38
- 201000010099 disease Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 241000710788 Lelystad virus Species 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 230000035935 pregnancy Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000000405 serological effect Effects 0.000 description 11
- 208000029523 Interstitial Lung disease Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000001850 reproductive effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 7
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 7
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 7
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 7
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 7
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 7
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 7
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 7
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 7
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 7
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 7
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 7
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 6
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 6
- 208000001726 Classical Swine Fever Diseases 0.000 description 6
- 206010020843 Hyperthermia Diseases 0.000 description 6
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 6
- 241000255969 Pieris brassicae Species 0.000 description 6
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000036031 hyperthermia Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 208000009305 pseudorabies Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 5
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 5
- 206010024769 Local reaction Diseases 0.000 description 5
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 5
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000007918 pathogenicity Effects 0.000 description 5
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 206010000210 abortion Diseases 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical group [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960000554 metrizamide Drugs 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 208000002254 stillbirth Diseases 0.000 description 2
- 231100000537 stillbirth Toxicity 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JMNQYAXOMXHZAP-ZETCQYMHSA-N (2s)-5-(diaminomethylideneamino)-2-(propylamino)pentanoic acid Chemical compound CCCN[C@H](C(O)=O)CCCNC(N)=N JMNQYAXOMXHZAP-ZETCQYMHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001292006 Arteriviridae Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 240000008213 Brosimum alicastrum Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 101100137193 Cassava vein mosaic virus ORF 3 gene Proteins 0.000 description 1
- 101100286205 Cassava vein mosaic virus ORF 4 gene Proteins 0.000 description 1
- 101100488875 Cassava vein mosaic virus ORF 5 gene Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 101001114132 Naja sputatrix Neutral phospholipase A2 B Proteins 0.000 description 1
- 101001114133 Naja sputatrix Neutral phospholipase A2 muscarinic inhibitor Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241001080180 Quinta Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101001120268 Streptomyces griseus Protein Y Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- PYOZTOXFQNWBIS-UHFFFAOYSA-N phenol;sodium Chemical compound [Na].OC1=CC=CC=C1 PYOZTOXFQNWBIS-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 235000005828 ramon Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
- C12N2770/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES9301973A ES2074950B1 (es) | 1993-09-17 | 1993-09-17 | Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda. |
| ES9301973 | 1993-09-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL9401414A NL9401414A (nl) | 1995-04-18 |
| NL194940B NL194940B (nl) | 2003-04-01 |
| NL194940C true NL194940C (nl) | 2003-08-04 |
Family
ID=8283072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9401414A NL194940C (nl) | 1993-09-17 | 1994-08-31 | Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. |
Country Status (7)
| Country | Link |
|---|---|
| DE (1) | DE4432338C2 (da) |
| DK (1) | DK173128B1 (da) |
| ES (1) | ES2074950B1 (da) |
| FR (1) | FR2709966B1 (da) |
| GB (1) | GB2282811B (da) |
| IT (1) | IT1267448B1 (da) |
| NL (1) | NL194940C (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69201441T3 (de) | 1991-06-06 | 2008-12-04 | Boehringer Ingelheim Vetmedica Gmbh | Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits. |
| US6042830A (en) * | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
| US6592873B1 (en) | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
| US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| US6773908B1 (en) | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| US6251397B1 (en) | 1992-10-30 | 2001-06-26 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same |
| US6380376B1 (en) | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| ES2078187B1 (es) * | 1994-05-13 | 1996-07-16 | Cynamid Iberica S A | Proteinas recombinantes de prrs, kits de diagnostico y vacunas que contienen dichas proteinas recombinantes. |
| GB2289279B (en) * | 1994-05-13 | 1998-09-16 | Iberica Cyanamid | Diagnostic kits and vaccines containing recombinant PRRSV proteins |
| US5690940A (en) * | 1995-06-21 | 1997-11-25 | Regents Of The University Of Minnesota | Low pathogencity PRRS live virus vaccines and methods of preparation thereof |
| EE04741B1 (et) * | 1996-03-01 | 2006-12-15 | Schering Corporation | Sigade sigimis- ja hingamissündroomi vaktsiin |
| US5866401A (en) * | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
| EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| EP1882696A3 (en) | 1997-05-06 | 2008-03-05 | Boehringer Ingelheim Vetmedica Gmbh | PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| CA2290220C (en) | 1998-12-22 | 2013-11-19 | Pfizer Products Inc. | An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof |
| CA2366072C (en) | 1999-03-08 | 2007-07-10 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Prrsv vaccines |
| MXPA01010681A (es) | 1999-04-22 | 2003-08-20 | Us Agriculture | Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado. |
| RU2232596C1 (ru) * | 2002-10-16 | 2004-07-20 | Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных | Способ изготовления вирус-вакцины против репродуктивно-респираторного синдрома свиней |
| RU2007101725A (ru) | 2004-06-18 | 2008-07-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота (Us) | Идентификация инфицированных вирусом и вакцинированных вирусом организмов |
| US7632636B2 (en) | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
| HUE025537T2 (en) | 2004-12-30 | 2016-05-30 | Boehringer Ingelheim Vetmedica Inc | PCV2-immunogenic compositions and methods for preparing such compositions |
| CA2894069C (en) | 2005-06-24 | 2019-02-26 | Regents Of The University Of Minnesota | Prrs viruses, infectious clones, mutants thereof, and methods of use |
| EP1968630B1 (en) | 2005-12-29 | 2018-01-24 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent pcv2 immunogenic compositions |
| RU2316346C2 (ru) * | 2006-02-20 | 2008-02-10 | Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ "ВНИИЗЖ") | Вакцина против репродуктивно-респираторного синдрома свиней эмульсионная инактивированная |
| AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| EP2558118B1 (en) * | 2010-04-16 | 2019-06-05 | Universiteit Gent | Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus |
| SG192821A1 (en) | 2011-02-17 | 2013-09-30 | Boehringer Ingelheim Vetmed | Commercial scale process for production of prrsv |
| ES2550258T3 (es) | 2011-02-17 | 2015-11-05 | Boehringer Ingelheim Vetmedica Gmbh | Nueva cepa del PRRSV europea |
| EP2737059A1 (en) | 2011-07-29 | 2014-06-04 | Boehringer Ingelheim Vetmedica GmbH | Novel prrs virus inducing type i interferon in susceptible cells |
| US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| WO2014150822A2 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
| EA039060B1 (ru) | 2013-12-20 | 2021-11-29 | Бёрингер Ингельхайм Ветмедика Гмбх | Вариант вируса ppcc, способ его получения с помощью молекулы нуклеиновой кислоты, конструкции днк или клетки и его применение для лечения и профилактики ррсс |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69201441T3 (de) * | 1991-06-06 | 2008-12-04 | Boehringer Ingelheim Vetmedica Gmbh | Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits. |
| AU2684792A (en) * | 1991-10-14 | 1993-05-21 | Akzo Nobel N.V. | Porcine reproductive respiratory syndrome vaccine and diagnostic |
| FR2686097B1 (fr) * | 1992-01-14 | 1994-12-30 | Rhone Merieux | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie. |
| KR100374295B1 (ko) * | 1993-02-08 | 2003-12-24 | 바이엘 코포레이션 | 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도 |
-
1993
- 1993-09-17 ES ES9301973A patent/ES2074950B1/es not_active Expired - Fee Related
-
1994
- 1994-08-31 NL NL9401414A patent/NL194940C/nl not_active IP Right Cessation
- 1994-09-06 DK DK199401028A patent/DK173128B1/da not_active IP Right Cessation
- 1994-09-07 FR FR9410722A patent/FR2709966B1/fr not_active Expired - Fee Related
- 1994-09-09 IT ITTO940713 patent/IT1267448B1/it active IP Right Grant
- 1994-09-10 DE DE19944432338 patent/DE4432338C2/de not_active Expired - Lifetime
- 1994-09-16 GB GB9418775A patent/GB2282811B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ITTO940713A1 (it) | 1996-03-09 |
| NL9401414A (nl) | 1995-04-18 |
| ITTO940713A0 (it) | 1994-09-09 |
| IT1267448B1 (it) | 1997-02-05 |
| NL194940B (nl) | 2003-04-01 |
| ES2074950B1 (es) | 1996-03-16 |
| GB2282811B (en) | 1998-02-18 |
| DE4432338C2 (de) | 1997-10-30 |
| DE4432338A1 (de) | 1995-05-04 |
| DK173128B1 (da) | 2000-01-31 |
| GB2282811A (en) | 1995-04-19 |
| FR2709966A1 (fr) | 1995-03-24 |
| GB9418775D0 (en) | 1994-11-02 |
| ES2074950A1 (es) | 1995-09-16 |
| DK102894A (da) | 1995-03-18 |
| FR2709966B1 (fr) | 1997-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL194940C (nl) | Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom. | |
| AU703084B2 (en) | Low pathogenicity prrs live virus vaccines and methods of preparation thereof | |
| Cook et al. | Preliminary antigenic characterization of an avian pneumovirus isolated from commercial turkeys in Colorado, USA | |
| ES2353952T3 (es) | Ácidos nucleicos que codifican para vacunas contra el virus del síndrome reproductivo y respiratorio porcino (prrsv). | |
| ES2349041T3 (es) | Derivados de hidantoina para el tratamiento de trastornos inflamatorios. | |
| US9579373B2 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| KR19990014840A (ko) | 불가사의한 돼지의 질병과 관련된 바이러스성 약제 | |
| TW201300538A (zh) | 新穎歐洲型ｐｒｒｓｖ株 | |
| US4904468A (en) | Canine coronavirus vaccine | |
| CN106554944A (zh) | 猪流行性腹泻病毒弱毒株及其制备的疫苗组合物和应用 | |
| CN107537031A (zh) | 一种预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用 | |
| RU2403063C1 (ru) | Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота | |
| JP4050312B2 (ja) | ニワトリ貧血因子ブロイラーワクチン | |
| JP7513614B2 (ja) | プライム－ブーストワクチン接種レジメン | |
| Yousif et al. | Oral administration of hyperimmune IgY: an immunoecological approach to curbing acute infectious bursal disease virus infection | |
| RU2395299C1 (ru) | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи, рота-, коронавирусной болезней и лептоспироза крупного рогатого скота | |
| RU2269361C2 (ru) | Вакцина ассоциированная эмульсионная инактивированная против репродуктивно-респираторного синдрома и парвовирусной инфекции свиней | |
| RU2395297C1 (ru) | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи и лептоспироза крупного рогатого скота | |
| HUP0202389A2 (hu) | Macskafélék calicivírus-betegsége elleni, inaktivált vakcina | |
| RU2817873C2 (ru) | Схема вакцинации "прайм-буст" | |
| Garmendia et al. | Porcine Reproductive and Respiratory Syndrome | |
| ES2349045T3 (es) | Composiciones y cepas del virus del sindrome reproductivo y respiratorio. | |
| KR20050040172A (ko) | 돼지 생식기호흡기 증후군 바이러스 불활화 백신의 제조방법 | |
| MXPA97010149A (en) | Live pathogenicity live virus vaccines and methods of preparation of mis | |
| MXPA99005452A (en) | Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1A | A request for search or an international-type search has been filed | ||
| BC | A request for examination has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BI | The patent application has been withdrawn | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Effective date: 20140831 |